Long-acting HIV Pre-Exposure Prophylaxis Integrated With Community-based Sexual and Reproductive Health in South Africa (LAPIS): A Hybrid (1a) Cluster Randomised Controlled Phase 3B Trial of Effectiveness and Implementation

The goal of this hybrid (1a) Cluster Randomised Controlled Trial phase 3B trial is to evaluate the effectiveness and implementation of offering a choice of HIV Pre-Exposure Products (PrEP) through community-based sexual and reproductive health services, on PrEP uptake and retention, and population prevalence of sexually transmissible HIV amongst adolescents and young adults living in rural South Africa.
Researchers will compare adding the choice of long-acting PrEP, i.e. two monthly injectable cabotegravir (CAB LA) or dapiravine vaginal ring and HIV post exposure prophylaxis packs to daily oral PrEP integrated with community-based SRH in the 20 intervention clusters with standard of care (SoC), daily oral PrEP integrated with community-based SRH in the 20 control clusters, on uptake and retention on PrEP. We hypothesise that offering a choice of long-acting or oral PrEP and PEP within the community-based delivery of SRH services will overcome the challenges and barriers to effective use of oral daily PrEP and lead to a population-level effect on uptake and retention on PrEP and thus the prevalence of sexually transmissible HIV amongst 15-30 year olds living in rural KwaZulu-Natal, South Africa.

Start Date27 Feb 2024

Sponsor / Collaborator-

NCT06807736

/ RecruitingNot ApplicableIIT

PrEPared to Choose (PtC): An Implementation Study of the Delivery of Cabotegravir Long-acting Injectable Pre-exposure Prophylaxis (PrEP) as an HIV Prevention Product Option Within a PrEP Choice Context in a Real World Setting in Cape Town.

The goal of this clinical trial is to offer adolescents and young people in Cape Town, South Africa different HIV pre-exposure prophylaxis (PrEP) products and describe how they use these products over an 18-month period. The study has both clinical and implementation primary aims. The primary clinical aim is short and long-term persistence on PrEP. Persistence is defined as the length of time that a participant shows continuous use of a PrEP product as intended, without stopping PrEP or switching to another PrEP product. The primary implementation aim involves the determination of factors that either enable or serve as a barrier to PrEP uptake and continuation.
Participants will be offered a choice between three antiretroviral-containing PrEP products: (1) a Tenofovir-based oral tablet that needs to be taken daily; (2) a vaginal ring containing Dapivirine that provides HIV protection for up to one month; and (3) an intramuscular injection containing Cabotegravir that provides HIV protection for up to two months. Participants will be able to use the same product throughout the study, switch between products, or stop and restart on PrEP at any point.
The study will be offered from two study sites: the first is a mobile clinic that rotates on a fixed schedule across the study area and the second is a fixed-location government primary healthcare clinic. The study will be open to confirmed HIV-negative individuals, including adolescent girls and young women (aged 15-29 years), young gender and sexually diverse populations aged 15-29 years (including men who have sex with men, transgender people, and non-binary people), and their collective sexual partners (including heterosexual, cisgender men) of any age.

Start Date13 Feb 2024

Sponsor / Collaborator

Desmond Tutu Hiv Foundation

[+2]

NCT05416021

/ CompletedPhase 1

A Phase I, Open-Label, Randomized, Crossover Trial to Investigate the Relative Bioavailability of the 25 mg Dapivirine Vaginal Ring-004 Inserted Every 30 Days and 100 mg DPV Ring-008 Inserted for 90 Days in Healthy Female Participants

A Phase I, Open-Label, Randomized, Crossover Trial to Investigate the Relative Bioavailability of the 25 mg Dapivirine Vaginal Ring-004 inserted every 30 days and 100 mg Dapivirine Vaginal Ring-008 inserted for 90 days in Healthy Female Participants

Start Date01 Aug 2022

Sponsor / Collaborator

INC Research Holdings, Inc.

100 Clinical Results associated with Dapivirine

100 Translational Medicine associated with Dapivirine

100 Patents (Medical) associated with Dapivirine

210

Literatures (Medical) associated with Dapivirine

20 Oct 2026·Sexual Health

Changes in sexual behavior among women in studies evaluating the dapivirine vaginal ring for HIV prevention

Article

Author: Garcia, Morgan ; Siva, Samantha ; Palanee-Phillips, Thesla ; Jacobson, Cindy E. ; Neradilek, Moni ; Akello, Carolyne A. ; Hlahla, Kudzai ; Mansoor, Leila E. ; Reddy, Krishnaveni ; Gati, Brenda ; Singh, Nishanta ; Mhlanga, Felix ; Balkus, Jennifer E.

Background:

Access to novel HIV prevention technologies often raise concerns of risk compensation. This analysis examined changes in the sexual behaviors of MTN 020/ASPIRE participants, a placebo controlled randomized control trial, who subsequently enrolled in MTN-025/HOPE, an open-label extension using the dapivirine vaginal ring.

Methods:

Both studies enrolled healthy, sexually active, HIV-negative women from Malawi, South Africa, Uganda and Zimbabwe. Longitudinal data on participants’ sexual behaviors, specifically sex with a nonprimary partner (past 3 months), and use of male or female condoms at the last vaginal sex act were compared between ASPIRE and HOPE. Conditional and mixed ordinal logistic regression models evaluated associations between study and sexual behaviors at enrollment, and quarterly over the first 12 months.

Results:

Of the 2629 individuals enrolled in ASPIRE, 1456 (55%) participated in HOPE. At enrollment, the proportion of participants who reported sex with a nonprimary partner and condom use at last vaginal sex act did not differ by study. Across all quarterly follow-up visits, sex with a nonprimary partner was more common in HOPE (13.9–18.7%) than ASPIRE (10.7–12.6%); adjusted OR 1.47, 95% CI 1.24–1.75, P < 0.001. There was no difference in condom use at the last vaginal act across all quarterly follow-up visits between ASPIRE (36.5–42.7%) and HOPE (43.6–46.7%); adjusted OR 1.05, 95% CI 0.94–1.18.

Conclusion:

More women reported sex with nonprimary partners in HOPE, with little change in condom use over time between the two studies. Understanding behavior changes during PrEP use allows for tailored, holistic reproductive health programming.

29 Sep 2026·ACS Omega

Systematic Structure–Activity Relationship Investigation on Novel 5-Alkyl-6-benzyl-2-{[(methylthio/phenylthio)alkyl]thio}-pyrimidin-4(3 H )-ones Endowed with Potent Anti-HIV-1 Activity

Article

Author: Bavagnoli, Laura ; Nawrozkij, Maxim B. ; Bianchi, Elena ; Ivanov, Roman ; Rotili, Dante ; Mai, Antonello ; Ragno, Rino ; Crespan, Emmanuele ; Esté, José A. ; Fiorentino, Francesco ; Hailu, Gebremedhin Solomon ; Voronkov, Andrey ; Chernyshov, Vladimir ; Astolfi, Roberta ; Mancini, Andrea ; Degtyarenko, Egor ; Golovina, Anastasia ; Fabbrizi, Emanuele

Abstract:

Four series of 5-alkyl-6-benzyl-2-[(methylthio/phenylthio)alkyl]thiopyrimidin-4(3H)-ones were systematically diversified at C2, C5, and C6 and evaluated as anti-HIV-1 agents. In MT-4 cells, these compounds displayed low-to-moderate cytotoxicity and subnanomolar-to-submicromolar inhibition of WT HIV-1, with potency governed by a balanced SAR. Ortho-dihalogenated C6-benzyl groups, particularly 2,6-F2 and 2,6-Cl2, were generally favored. In the 2,6-dihalobenzyl series, optimal activity required C5 methyl combined with para-substituted phenylthiomethyl groups at C2, whereas 3,5-Me2-benzyl analogues benefited from C5 isopropyl paired with methylthioethyl (24l) or unsubstituted phenylthiomethyl (24m) C2 side chains. The p-methoxyphenylthiomethyl thiothymine derivatives 21e (2,6-F2) and 23e (2,6-Cl2) emerged as lead inhibitors, showing high selectivity, potent activity against WT and clinically relevant HIV-1 variants, superior efficacy compared with nevirapine and efavirenz, dapivirine-like potency, and improved resistance tolerance relative to phenethyl-S-DABO bioisosteres. Together, biological and QSAR and docking data contribute to defining optimization strategies aimed at achieving durable anti-HIV-1 activity within the investigated chemotype and support further development of next-generation NNRTIs with improved efficacy against clinically relevant HIV-1 strains.

02 Sep 2026·AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV

A qualitative exploration of women’s choices and experiences of using oral and vaginal HIV pre-exposure prophylaxis in Eswatini

Article

Author: Mmema, Nqobile ; Dlamini, Sinikiwe ; Ciglenecki, Iza ; Dlamini, Velibanti ; Wringe, Alison ; Daka, Michelle ; Kerschberger, Bernhard ; Flores, Antonio ; Lekelem, Skinner ; Mabhena, Edwin ; Mukooza, Esther ; Matse, Sindy

Understanding women's decision-making when offered different HIV pre-exposure prophylaxis (PrEP) options is critical for improving uptake. This qualitative study explored factors influencing PrEP choices among Swazi women in 2022-2023. In-depth interviews were conducted with 17 women who accepted or declined oral PrEP or the Dapivirine vaginal ring; and 6 healthcare workers who prescribed PrEP. One focus group discussion (FGD) with eight women eligible for PrEP and three FGDs with six to eight male community members explored attitudes to PrEP. Data were collected in Siswati, transcribed into English, and analyzed thematically. Women's decisions around PrEP use and product preferences were shaped by social norms around sexual relationships, practicalities of use and perceptions of effectiveness. Many preferred "invisible" methods, such as the ring, to avoid stigma or partner violence, while oral PrEP was favored by some women practicing anal sex. Ease of adherence, side-effects and ring insertion practicalities also influenced choices. Some participants questioned PrEP effectiveness or feared it might spread HIV, while some healthcare workers noted that future injectable options could reduce blame in cases of seroconversion. The findings highlight the need to offer women a range of PrEP options, supported by accurate information, to expand coverage in high-incidence settings.

News (Medical) associated with Dapivirine

19 May 2026

·www.cidrz.org

CIDRZ CHEP Pays Courtesy Call on Central Province Health Office During Lenacapavir Training in Kabwe.

CIDRZ’s Controlling HIV Epidemic Project (CHEP) paid a courtesy call on the Central Province Health Office in Kabwe as part of ongoing activities related to the transitioning of the Zambia Integrated Health (ZIH) program, from Pact Inc. to CIDRZ. During the same period, CIDRZ, in collaboration with the Ministry of Health, is conducting a Trainer of Trainers (ToT) workshop focused on the rollout of pre-exposure prophylaxis (PrEP) products, namely, cabotegravir, Dapivirine Vaginal Ring (DVR) and Lenacapavir, a groundbreaking HIV prevention intervention described by experts as the closest alternative to an HIV vaccine. The PrEP workshop aims to equip frontline healthcare workers with the knowledge and skills required to effectively deliver the different PrEP products as Zambia strengthens efforts towards HIV epidemic control. The CHEP delegation was led by Ms Francheskie Vélez, Director of the Health Coordination Office at the U.S. Embassy in Zambia and included CHEP Chief of Party Dr Maurice Musheke. Speaking during the visit, Ms Vélez reaffirmed the U.S. Government’s commitment, through the U.S. Embassy in Zambia, to strengthening partnerships with local organisations to implement life-saving health interventions. She noted that CIDRZ had been identified as an ideal local partner as the U.S. Government shifts focus on prioritising local organisations to lead and sustain public health programmes. Ms Vélez also thanked the Provincial Health Office for hosting the team and supporting the successful implementation of the training programme in Kabwe. The Provincial Health Director, Dr Elijah Mutoloki, was represented by Dr Mwanja Kakusa, the Provincial Clinical Care Specialist for Central Province, who welcomed the delegation and expressed appreciation for selecting Kabwe as the host district for the training. Dr Kakusa noted that the Training of Trainers workshop was particularly important because Central Province had not been included in the previous training. She added that the healthcare workers participating in the training would play a critical role in cascading the knowledge and skills acquired to other healthcare workers across the province. Dr Kakusa further stated that the training would strengthen the province’s HIV response by enhancing healthcare workers’ capacity to deliver innovative HIV prevention services as the province seeks to achieve epidemic control. CIDRZ continues to work closely with the Ministry of Health, the U.S. Government through the U.S. Embassy in Zambia, and other partners to support evidence-based interventions that improve health outcomes and advance Zambia’s HIV response.

Clinical Study

22 Apr 2026

·www.cidrz.org

CIDRZ, Ministry of Health Train HIV Specialists in Advanced PrEP Delivery to Strengthen Prevention Efforts.

To strengthen HIV prevention efforts, the Controlling HIV Epidemic Project (CHEP), under the Centre for Infectious Disease Research in Zambia (CIDRZ), in collaboration with the Ministry of Health and with financial support from the United States Department of State, conducted a six-day Training of Trainers (ToT) workshop on the delivery of different pre-exposure prophylaxis (PrEP) products. The training which was held in Ndola, brought together HIV healthcare specialists from CIDRZ, the Copperbelt Provincial Health Office, Ndola Teaching Hospital, Copperbelt District Health Offices, and the United States Department of State. Participants were drawn from Eastern, Western, Lusaka, and Copperbelt provinces. The training was officially opened by Copperbelt Provincial Health Director, Dr Charles Mwinuna, and focused on equipping participants with the skills required to deliver combination HIV prevention services. Particular emphasis was placed on oral PrEP, Cabotegravir (2-month injectable PrEP), Lenacapavir (6-month injectable PrEP), and the Dapivirine Vaginal Ring (DVR), a long-acting, user-controlled PrEP product designed to reduce the risk of acquiring HIV during vaginal sex. Meanwhile, Dr Paul Mwale, Copperbelt Provincial Advanced HIV Disease (AHD) and Injectable PrEP Coordinator under the Ministry of Health, led a session outlining the mandate of the HIV Prevention Programme, which aims to achieve epidemic control and end AIDS by 2030. He highlighted national targets, including reducing new HIV infections from 28,000 to 15,000 by 2026 and increasing PrEP uptake among key and priority populations to 220,000 annually, emphasising the need for accelerated efforts to meet both national and global goals. In another session, Dr Monica Chibesakunda, CIDRZ’s HIV Testing and Prevention Lead, trained participants on HIV testing services, stressing their role in both preventing new infections and linking individuals to care. She emphasised adherence to national HIV testing guidelines for PrEP initiation and the importance of providing tailored prevention services based on individual risk. Other sessions covered demand generation for PrEP, scheduling PrEP clinical visits, managing beneficiaries who missed appointments, switching beneficiaries between PrEP products, pharmacovigilance, and comprehensive data documentation. The training also addressed the link between Gender-Based Violence (GBV), Intimate Partner Violence (IPV), and HIV risk. Facilitators underscored the importance of integrating GBV and IPV screening into HIV services to support comprehensive, client-centred care. The workshop concluded with participants committing to cascade the knowledge gained and strengthen HIV prevention services, contributing to Zambia’s goal of ending AIDS as a public health threat by 2030.

Clinical Study

18 Jan 2023

·pipelinereview.com

Janssen and Global Partners to Discontinue Phase 3 Mosaico HIV Vaccine Clinical Trial

Independent, scheduled review of Phase 3 Mosaico study finds investigational vaccine regimen lacks efficacy in preventing HIV No vaccine-related safety issues identified LEIDEN, THE NETHERLANDS I January 18, 2023 I The Janssen Pharmaceutical Companies of Johnson & Johnson, together with a consortium of global partners, today announced the results of an independent, scheduled data review of the Phase 3 Mosaico study (also known as HPX3002/HVTN706) of Janssen’s investigational HIV vaccine regimen. The study’s independent Data and Safety Monitoring Board (DSMB) determined that the regimen was not effective in preventing HIV infection compared to placebo among study participants. No safety issues with the vaccine regimen were identified. In light of the DSMB’s determination, the Mosaico clinical trial will be discontinued. Participant notifications and further analyses of the data are underway. Throughout the trial, study investigators have ensured that any individuals who contracted HIV received prompt HIV treatment and care. “We are disappointed with this outcome and stand in solidarity with the people and communities vulnerable to and affected by HIV,” said Penny Heaton, M.D., Global Therapeutic Area Head, Vaccines, Janssen Research & Development, LLC. “Though there have been significant advances in prevention since the beginning of the global epidemic, 1.5 million people acquired HIV in 2021 alone, underscoring the high unmet need for new options and why we have long worked to tackle this global health challenge. We remain steadfast in our commitment to advancing innovation in HIV, and we hope the data from Mosaico will provide insights for future efforts to develop a safe and effective vaccine. We are grateful to our Mosaico partners and the study investigators, staff and participants.” About the Phase 3 Mosaico Study Mosaico, a Phase 3 study of Janssen’s investigational HIV vaccine regimen, began in 2019, and completed vaccinations in October 2022. The study included approximately 3,900 cisgender men and transgender people who have sex with cisgender men and/or transgender people, who represent groups and populations vulnerable to HIV, at over 50 trial sites in Argentina, Brazil, Italy, Mexico, Peru, Poland, Puerto Rico, Spain and the United States. The study evaluated an investigational vaccine regimen containing a mosaic-based adenovirus serotype 26 vector (Ad26.Mos4.HIV) administered during four vaccination visits over one year. A mix of soluble proteins (Clade C/Mosaic gp140, adjuvanted with aluminum phosphate) was also administered at visits three and four. The Mosaico DSMB analysis, based on the data available to date, indicated that the regimen does not protect against HIV and the study is not expected to meet its primary endpoint. No safety issues with the vaccine regimen were identified. In light of this, the study will be discontinued, and further analyses are underway. The DSMB’s determination follows the primary analysis of the Phase 2b Imbokodo study, which was announced in August 2021 and found that a similar investigational HIV vaccine regimen did not provide sufficient protection against HIV in a population of young women in sub-Saharan Africa. The investigational vaccine regimen used in the Imbokodo study was found to have a favorable safety profile. The Mosaico study was led by a global public-private partnership including the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), the HIV Vaccine Trials Network (HVTN), the U.S. Army Medical Research and Development Command (USAMRDC), and Janssen Vaccines & Prevention B.V. Since 2005, Janssen Vaccines & Prevention B.V. has been participating as a sub-grantee in the NIH-supported Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) program under grants AI066305, AI078526, AI096040 and AI128751 (Principal Investigator, Prof. Dan Barouch). Johnson & Johnson’s Commitment to HIV Johnson & Johnson has been committed to the fight against HIV for decades, playing a key role in bringing nine therapeutics to people living with HIV and continuing to drive innovation in HIV prevention and care. In January 2021, the dapivirine ring, a discreet long-acting HIV prevention method specifically developed for women by the International Partnership for Microbicides (IPM) and based on Janssen’s compound, was recommended by the World Health Organization as an additional prevention choice for women with a substantial chance of contracting HIV as part of combination prevention approaches. In July 2021 , Zimbabwe became the first country to approve the use of the dapivirine ring among women ages 18 and older, with South Africa following suit in March 2022 . Additional regulatory decisions are pending. Johnson & Johnson also works with vulnerable communities on the frontlines of the HIV epidemic, and has supported collaborative initiatives like the DREAMS Partnership in sub-Saharan Africa, the MenStar Coalition , and the New Horizons Collaborative . To learn more about Johnson & Johnson’s commitment to combatting HIV, please visit jnj.com/hiv . About Johnson & Johnson At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities, and forward progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest diversified healthcare products company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body, and environment within reach of everyone, everywhere. We are blending our heart, science, and ingenuity to profoundly change the trajectory of health for humanity. About the Janssen Pharmaceutical Companies of Johnson & Johnson At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension. Learn more at http://www.janssen.com and follow us at http://www.twitter.com/JanssenGlobal and www.twitter.com/JanssenUS . Janssen Vaccines & Prevention, B.V. and Janssen Research & Development, LLC are part of the Janssen Pharmaceutical Companies of Johnson & Johnson. SOURCE: Johnson & Johnson

VaccinePhase 2Phase 3Clinical Result

100 Deals associated with Dapivirine

External Link

KEGG	Wiki	ATC	Drug Bank
D11246	Dapivirine	G01AX17	DB08639

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Infections	Phase 3	Kenya	INC Research Holdings, Inc.	01 Jul 2011
HIV Infections	Phase 3	Kenya	International Partnership for Microbicides	01 Jul 2011
HIV Infections	Phase 3	Malawi	INC Research Holdings, Inc.	01 Jul 2011
HIV Infections	Phase 3	Rwanda	INC Research Holdings, Inc.	01 Jul 2011
HIV Infections	Phase 3	Rwanda	International Partnership for Microbicides	01 Jul 2011
HIV Infections	Phase 3	South Africa	INC Research Holdings, Inc.	01 Jul 2011
HIV Infections	Phase 3	Zimbabwe	INC Research Holdings, Inc.	01 Jul 2011
Acquired Immunodeficiency Syndrome	Phase 2	South Africa	International Partnership for Microbicides	01 Jul 2009
Acquired Immunodeficiency Syndrome	Phase 2	South Africa	INC Research Holdings, Inc.	01 Jul 2009
Contraception	Phase 1	United States	International Partnership for Microbicides	17 Jul 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03965923 (MTN-042/DELIVER, Pubmed \| Lancet HIV)	Phase 3	HIV Infections	251	Dapivirine vaginal ring	ehxwjzhtcd(adukduxduv) = zhtahgmdgx pjtkabgzsg (wvjtzyviis ) View more	Positive	01 Mar 2026
NCT03965923 (MTN-042/DELIVER, Pubmed \| Lancet HIV)	Phase 3	HIV Infections	545	Dapivirine vaginal ring	outaftbhoa(qkcwfpffpv) = zhgwacxtlg dpmgsazbhp (ijvmuzltlm ) View more	Positive	01 Nov 2025
				Oral PrEP (tenofovir disoproxil fumarate plus emtricitabine)	outaftbhoa(qkcwfpffpv) = qwlgcqjcix dpmgsazbhp (ijvmuzltlm ) View more
NCT04140266 (MTN-043, Pubmed \| Lancet HIV)	Phase 3	Breast Feeding	197	Dapivirine vaginal ring (DVR)	rpddhemlxb(micjckpudz) = nczlshxrwk ijukyukjzi (qmjfjwyjcu )	Positive	01 Mar 2025
IAS2024	Phase 2	HIV Infections	60	Truvada	vhgrapcbpz(usgpgxejdm) = iaqcclsmqh durskggsyr (deztmiokhm )	Positive	22 Jul 2024
				Dapivirine ring	vhgrapcbpz(usgpgxejdm) = nwtfjzxhxe durskggsyr (deztmiokhm )
MTN-042/DELIVER (IAS2024)	Phase 3	HIV Infections	154	Dapivirine Vaginal Ring	uauzhjnwmd(jmmkfpxqvw) = fqkflfhpyj fjxosuvzzp (udqrivgmzg )	Negative	22 Jul 2024
				Truvada	uauzhjnwmd(jmmkfpxqvw) = kljqohegys fjxosuvzzp (udqrivgmzg )
NCT01617096 (MTN-020/ASPIRE, Pubmed \| J Infect Dis)	Phase 3	HIV Infections	-	Dapivirine Vaginal Ring	oriiwpxloz(zlrtcbdova) = avhvguqpux mwlfpxsoce (jotwhjveca, 1.8 - 3.1)	Positive	12 Apr 2024
				Placebo	oriiwpxloz(zlrtcbdova) = wassabhwvh mwlfpxsoce (jotwhjveca, 2.9 - 4.4)
NCT01539226 (The Ring Study, Pubmed \| BMJ Open) Manual	Not Applicable	HIV Infections	197	Dapivirine vaginal ring / placebo vaginal ring	zzrqnfbbaz(llaxsanuvj) = mvpsxcnvqx pzsyfgkbby (hlvwgvxhgu, 44.7 - 60.3) View more	Negative	08 Apr 2024
				Dapivirine vaginal ring	zzrqnfbbaz(llaxsanuvj) = fnpbmyvioc pzsyfgkbby (hlvwgvxhgu )
NCT01617096 (MTN-020/ASPIRE \| ASPIRE \| MTN-020, CTgov)	Phase 3	HIV Infections	2,629	Dapivirine Vaginal Ring (Dapivirine Vaginal Ring)	oxnamibhav = fedzffiebi yqkruexwjv (wakpetuvnd, jcdwgkxuho - gdpabidztw) View more	-	16 Dec 2022
				Placebo Ring (Placebo Ring)	oxnamibhav = yhkiuljsjg yqkruexwjv (wakpetuvnd, oezdnkxbzv - bvnhwpntig) View more
NCT02862171 \| NCT01539226 (The Ring Study and DREAM, Pubmed)	Phase 3	HIV Infections	-	Dapivirine Vaginal Ring-004 (DVR)	eectlekxtl(vsqqfpqhbh) = bgvwqtlvhg ldwhvzhrvr (mottezdqgf )	-	08 Nov 2022
NCT02858037 (HOPE, CTgov)	Phase 3	HIV Infections	1,456	Dapivirine Vaginal Ring	pmugnoentt = ajnysivffm xocnoqxgsz (ndumnmleax, loobunpghl - ikyxwgawsh) View more	-	25 Oct 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis